» Articles » PMID: 28861501

Palmitoylethanolamide Modulates GPR55 Receptor Signaling in the Ventral Hippocampus to Regulate Mesolimbic Dopamine Activity, Social Interaction, and Memory Processing

Overview
Specialty Pharmacology
Date 2017 Sep 2
PMID 28861501
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The GPR55 receptor has been identified as an atypical cannabinoid receptor and is implicated in various physiological processes. However, its functional role in the central nervous system is not currently understood. The presence of GPR55 receptor in neural regions such as the ventral hippocampus (vHipp), which is critical for cognition, recognition memory, and affective processing, led us to hypothesize that intra-vHipp GPR55 transmission may modulate mesolimbic activity states and related behavioral phenomena. The vHipp is involved in contextual memory and affective regulation through functional interactions with the mesolimbic dopamine system. Using a combination of electrophysiology and behavioral pharmacological assays in rats, we tested whether intra-vHipp activation of GPR55 receptor transmission with the fatty acid amide, palmitoylethanolamide (PEA), a lipid neuromodulator with agonist actions at the GPR55 receptor, may modulate mesolimbic dopaminergic activity states. We further examined the potential effects of intra-vHipp PEA in affective, cognitive and contextual memory tasks. We report that intra-vHipp PEA produces a hyper-dopaminergic state in the mesolimbic system characterized by increased firing and bursting activity of ventral tegmental area dopaminergic neuron populations. Furthermore, while PEA-induced activation of GPR55 transmission had no effects on opiate-related reward-related memory formation, we observed strong disruptions in social interaction and recognition memory, spatial location memory, and context-independent associative fear memory formation. Finally, the effects of intra-vHipp PEA were blocked by a selective GPR55 receptor antagonist, CID160 and were dependent upon NMDA receptor transmission, directly in the vHipp. The present results add to a growing body of evidence demonstrating important functional roles for GPR55 signaling in cannabinoid-related neuronal and behavioral phenomena and underscore the potential for GPR55 signaling in the mediation of cannabinoid-related effects independently of the CB1/CB2 receptor systems.

Citing Articles

Treatment of Established Chemotherapy-Induced Neuropathy with N-Palmitoylethanolamide: A Randomized, Double-Blind Phase II Pilot Study.

Davis M, Ulrich A, Segal R, Gudena V, Ruddy K, DAndre S Cancers (Basel). 2025; 16(24.

PMID: 39766143 PMC: 11674762. DOI: 10.3390/cancers16244244.


Therapeutic Potential of Palmitoylethanolamide in Gastrointestinal Disorders.

Brankovic M, Gmizic T, Dukic M, Zdravkovic M, Daskalovic B, Mrda D Antioxidants (Basel). 2024; 13(5).

PMID: 38790705 PMC: 11117950. DOI: 10.3390/antiox13050600.


GPR55 is expressed in glutamate neurons and functionally modulates drug taking and seeking in rats and mice.

He Y, Shen H, Bi G, Zhang H, Soler-Cedeno O, Alton H Transl Psychiatry. 2024; 14(1):101.

PMID: 38374108 PMC: 10876975. DOI: 10.1038/s41398-024-02820-3.


Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA-ergic activity and cortical plasticity in long COVID-19 syndrome.

Versace V, Ortelli P, Dezi S, Ferrazzoli D, Alibardi A, Bonini I Clin Neurophysiol. 2022; 145:81-88.

PMID: 36455453 PMC: 9650483. DOI: 10.1016/j.clinph.2022.10.017.


Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders.

Assogna M, Di Lorenzo F, Martorana A, Koch G Biomolecules. 2022; 12(8).

PMID: 36009055 PMC: 9405819. DOI: 10.3390/biom12081161.


References
1.
Iannotti F, Di Marzo V, Petrosino S . Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog Lipid Res. 2016; 62:107-28. DOI: 10.1016/j.plipres.2016.02.002. View

2.
Yang H, Zhou J, Lehmann C . GPR55 - a putative "type 3" cannabinoid receptor in inflammation. J Basic Clin Physiol Pharmacol. 2015; 27(3):297-302. DOI: 10.1515/jbcpp-2015-0080. View

3.
Sharir H, Abood M . Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther. 2010; 126(3):301-13. PMC: 2874616. DOI: 10.1016/j.pharmthera.2010.02.004. View

4.
Henstridge C, Balenga N, Ford L, Ross R, Waldhoer M, Irving A . The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J. 2008; 23(1):183-93. DOI: 10.1096/fj.08-108670. View

5.
Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo F . Evidence for novel cannabinoid receptors. Pharmacol Ther. 2005; 106(2):133-45. DOI: 10.1016/j.pharmthera.2004.11.005. View